NEULAND LAB LTD.

Neuland Laboratories Limited conducted its Q1 FY27 earnings conference call on August 5, 2026, where management reported a total income of INR 650.1 crores, reflecting a 16.3% growth compared to the previous year. The CEO, Saharsh Davuluri, highlighted strong performance in both the GDS and CMS segments, with key products contributing significantly to revenue. The EBITDA for the quarter was INR 231.1 crores, with a margin of 35.5%. Management noted improvements in working capital efficiency, reducing days from 137 to 84. They discussed ongoing investments in R&D and capacity expansion, particularly in peptides, and emphasized the importance of strategic partnerships, such as the collaboration with Gland Pharma. The management acknowledged the inherent variability in their business and reiterated a cautious but optimistic view on growth for FY27 and FY28, focusing on execution and long-term value creation.

Management emphasized strong financial performance and strategic growth initiatives.